What are HER2-targeted monoclonal antibody drugs?

HER2-targeted monoclonal antibody drugs are pharmacologic agents that share a common mechanism (typically targeting HER2 (human epidermal growth factor receptor 2)). 2 are currently marketed, with 8 more in clinical development.

What are the marketed HER2-targeted monoclonal antibody drugs?

Marketed HER2-targeted monoclonal antibody drugs include Herceptin Hylecta®, trastuzumab (H).

HER2-targeted monoclonal antibody

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

2 marketed 8 in Phase 3

This page covers all HER2-targeted monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HER2 (human epidermal growth factor receptor 2), HER2 (Human Epidermal Growth Factor Receptor 2).

Targets

HER2 (human epidermal growth factor receptor 2) · HER2 (Human Epidermal Growth Factor Receptor 2)

Marketed (2)

Herceptin Hylecta® · Biocon Biologics UK PLC · Oncology
Herceptin Hylecta is a subcutaneous formulation of trastuzumab that binds to HER2 receptors on cancer cells to block growth signaling and trigger immune-mediated cell death.
trastuzumab (H) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Oncology
Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.

Phase 3 pipeline (8)

Herceptin (trastuzuamb) · Samsung Bioepis Co., Ltd. · Oncology
Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.
Herceptin SC [trastuzumab] · Hoffmann-La Roche · Oncology
Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.
Trastuzumab Injectable Product · Spanish Breast Cancer Research Group · Oncology
Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.
Pertuzumab (ZRC-3277) · Zydus Lifesciences Limited · Oncology
Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling.
TX05 (trastuzumab) · Tanvex BioPharma USA, Inc. · Oncology
Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.
Trastuzumab Injection · Spanish Breast Cancer Research Group · Oncology
Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.
Trastuzumab Injectable Solution · Spanish Breast Cancer Research Group · Oncology
Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.
Herceptin IV [trastuzumab] · Hoffmann-La Roche · Oncology
Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.

Patent intelligence

her2 targeted monoclonal antibody patent landscape — aggregated cliff calendar, attackable patents, originator estates